Tamás Barbai

Tamás Barbai

Auto-generated profile, based on publicly available information

Tamás Barbai

2nd Department of Pathology, Semmelweis University, 1091 Budapest, Hungary

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in European Journal of Cancer
Verified
Journal Article
Open access
MCMihály Cserepes
Mihály Cserepes
GOGyula Ostoros
Gyula Ostoros
ZLZoltan Lohinai
Zoltan Lohinai
ERErzsebet Raso
Erzsebet Raso
TBTamas Barbai
Tamas Barbai
ÁGÁron Kristof Ghimessy
Áron Kristof Ghimessy
Platinum-based chemotherapy is the most common treatment in advanced-stage lung adenocarcinoma. Because the clinical significance of KRAS mutational status in this setting has not yet been clearly determined, a mutation subtype-specific analysis was performed in the so far largest cohort of Caucasian patients with KRAS mutant advanced-stage lung adenocarcinoma treated with platinum-based chemotherapy. 505 Caucasian stage III-IV lung adenocarcinoma patients with known amino acid substitution-specific KRAS mutational status and treated with platinum-based chemotherapy were included. The correlations of subtype-specific KRAS mutations with smoking status, progression-free and overall survival (PFS and OS, respectively) and therapeutic response were analysed. Among 338 KRAS wild-type, 147 codon 12 mutant and 20 codon 13 mutant patients, there were no mutation-related significant differences in PFS or OS (P values were 0.534 and 0.917, respectively). Eastern Cooperative Oncology Group (ECOG) status and clinical stage were significant independent prognostic factors. KRAS mutation showed a significant correlation with smoking status (P=0.018). Importantly, however, G12V KRAS mutant patients were significantly more frequent among never-smokers than all other codon 12 KRAS mutant (G12x) subtypes (P=0.016). Furthermore, this subgroup tended to have a higher response rate (66% versus 47%; P=0.077). A modestly longer median PFS was also found in the G12V mutant cohort (233days; versus 175days in the G12x group; P=0.145). While KRAS mutation status per se is neither prognostic nor predictive in stage III-IV lung adenocarcinoma, subtype-specific analysis may indeed identify clinically relevant subgroups of patients that may ultimately influence treatment decisions.

12 June 2012 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
Tibor KrenacsTibor Krenacs
Tibor Krenacs
GKG. Kiszner
G. Kiszner
ESE. Stelkovics
E. Stelkovics
PBP. Balla
P. Balla
ITI. Teleki
I. Teleki
ERE. Raso
E. Raso

1 January 2012 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
BBBalázs Bánky
Balázs Bánky
LRLívia Rásó-Barnett
Lívia Rásó-Barnett
TBTamás Barbai
Tamás Barbai
JTJozsef Timar
Jozsef Timar
PBPéter Becságh
Péter Becságh
ERErzsébet Rásó
Erzsébet Rásó
CD44 is considered as ‘a’ metastasis associated gene, despite the fact that it is an umbrella term for a group of molecules produced from a single gene by alternative splicing. However, little consideration is given to the above in the literature of colorectal carcinomas as well as other tumour types, leading to confusion and contradictory results about its possible role in tumour progression.

31 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
TBTamás Barbai
Tamás Barbai
ZFZsuzsanna Fejős
Zsuzsanna Fejős
LPLaszlo G. Puskas
Laszlo G. Puskas
JTJózsef Tímár
József Tímár
ERErzsébet Rásó
Erzsébet Rásó
The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma

17 November 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AVA. Vatankhah
A. Vatankhah
JHJ. Halász
J. Halász
VPV. Piurkó
V. Piurkó
TBT. Barbai
T. Barbai
ERE. Rásó
E. Rásó
JTJozsef Timar
Jozsef Timar
The local immune responses to chronic echinococcal infections in various organs are largely unknown. Since the liver is the most frequently involved organ in such infections in human we aimed to characterize the inflammatory as well as immune cell infiltrate around hydatid cysts in the liver and compared to common inflammatory processes of the liver. Surgical samples from the liver of 21 cystic echinococcosis (CE) patients were studied and the distribution of different types of inflammatory and immune cells were determined by immunohistochemistry. Furthermore, expression levels of costimulatory CTLA4, CD28, CD80 and CD86 molecules were measured at RNA level by PCR. Liver biopsy samples from patients with steatohepatitis (SH, n = 11) and chronic hepatitis (CH, n = 11) were used as non-inflammatory and chronic inflammatory controls, respectively. The composition and density of the inflammatory and immune cell infiltrates have been compared by using morphometry. CD3+ T cells predominated the inflammatory infiltrate in all pathological processes, while in CE samples CD20+ B cells, in CH samples CD68+ macrophages were also frequent. Both myeloperoxidase (MPO) + leukocytes and CD68+ macrophages were found to be significantly decreased in CE as compared to either SH or CH samples. Concerning T cell subtypes, only CD8+ T cells were found to be significantly decreased in SH samples. CD1a + dendritic cells were almost completely missing from CE biopsies unlike in any other sample types. There were no differences detected in the mRNA expression of costimulatory molecules except decreased expression of CD28 in CE samples. In the hydatid lesions of the liver of chronic echinococcal infections T cell-mediated immunity seems to be impaired as compared to other types of chronic inflammatory processes, suggesting an immunosuppressive role for Echinococcus granulosus, which deserve further attentions.

9 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AGAron Kristof Ghimessy
Aron Kristof Ghimessy
ÁGÁron Bertram Gellért
Áron Bertram Gellért
ESErzsebet Schlegl
Erzsebet Schlegl
BHBalazs Hegedus
Balazs Hegedus
ERErzsebet Raso
Erzsebet Raso
ÁGÁron Kristof Ghimessy
Áron Kristof Ghimessy
Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angiogenesis has been well established, its prognostic and predictive role in the above setting remains unclear. The association between KRAS exon 2 mutational status and clinicopathological variables including progression-free survival and overall survival (PFS and OS, respectively) was retrospectively analyzed in 501 Caucasian stage IIIB-IV LADC patients receiving first-line platinum-based chemotherapy (CHT) with or without bevacizumab (BEV). EGFR (epidermal growth factor receptor)-mutant cases were excluded. Of 247 BEV/CHT and 254 CHT patients, 95 (38.5%) and 75 (29.5%) had mutations in KRAS, respectively. KRAS mutation was associated with smoking (p = 0.008) and female gender (p = 0.002) in the BEV/CHT group. We found no difference in OS between patients with KRAS-mutant versus KRAS wild-type tumors in the CHT-alone group (p = 0.6771). Notably, patients with KRAS-mutant tumors demonstrated significantly shorter PFS (p = 0.0255) and OS (p = 0.0186) in response to BEV/CHT compared to KRAS wild-type patients. KRAS mutation was an independent predictor of shorter PFS (hazard ratio, 0.597; p = 0.011) and OS (hazard ratio, 0.645; p = 0.012) in the BEV/CHT group. G12D KRAS-mutant patients receiving BEV/CHT showed significantly shorter PFS (3.7 months versus 8.27 months in the G12/13x group; p = 0.0032) and OS (7.2 months versus 16.1 months in the G12/13x group; p = 0.0144). In this single-center, retrospective study, KRAS-mutant LADC patients receiving BEV/CHT treatment exhibited inferior PFS and OS compared to those with KRAS wild-type advanced LADC. G12D mutations may define a subset of KRAS-mutant LADC patients unsuitable for antiangiogenic therapy with BEV.